Abstract | BACKGROUND: Real-time quantitative RT-PCR (RQ-PCR) assay has become a vital tool to monitor residual disease of leukemia. However, the complexity and standardization of RQ-PCR should never be overlooked and the results should be interpreted cautiously in clinical conditions. We aimed to assess the methodology of RQ-PCR and its clinical applications in monitoring molecular kinetics of 36 newly diagnosed cases of acute promyelocytic leukemia patients with t (15; 17) from October 2004 to December 2005. METHODS: RESULTS: The sensitivity of RQ-PCR was 1 per 10(5) cells and 5 copies of the PML-RARalpha transcript could be reproducibly detected. No false positive results occurred in 40 non- acute promyelocytic leukemia samples. Optimal amplification efficiency could be attained, which was determined by the slope of the standard curves (slope: -3.2 - -3.7). The inter-assay and intra-assay variation coefficients of the method were 1.01% and 0.56% respectively. Although the time to attain hematological complete remission was similar in both groups, the time to achieve molecular remission of group 1 was significantly shorter than that of group 2 (61 days vs 75 days, P = 0.034). The rate of molecular remission within 70 days was higher in group 1 than in group 2 (75.00% vs 38.46%, P = 0.036). Compared with pretreatment, median reduction of the PML-RARalpha transcript before first consolidation therapy differed significantly between group 1 and group 2 (log scale, 3.15 vs 2.31, P = 0.024). Interestingly, we found that PML-RARalpha transcript levels temporarily increased in bone marrow (7 patients) and peripheral blood (22 patients) samples of patients during induction therapy in both groups. CONCLUSIONS:
|
Authors | Hong-hu Zhu, Yan-rong Liu, Ya-zhen Qin, Bin Jiang, Fu-xiang Shan, Shu-lan Wu, Ping-di Yang, Jie Zhao, Dao-pei Lu |
Journal | Chinese medical journal
(Chin Med J (Engl))
Vol. 120
Issue 20
Pg. 1803-8
(Oct 20 2007)
ISSN: 0366-6999 [Print] China |
PMID | 18028775
(Publication Type: Journal Article)
|
Chemical References |
- Oncogene Proteins, Fusion
- RNA, Messenger
- promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
|
Topics |
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Child
- Female
- Humans
- Leukemia, Promyelocytic, Acute
(blood, drug therapy, genetics)
- Male
- Middle Aged
- Oncogene Proteins, Fusion
(genetics)
- RNA, Messenger
(analysis)
- Reverse Transcriptase Polymerase Chain Reaction
(methods)
- Sensitivity and Specificity
|